A Drug-Free Pathogen Capture and Neutralizing Nasal Spray to Prevent Emerging Respiratory Infections
J. Joseph, H. M. Baby, J. R. Quintero, D. Kenney, Y. Mebratu, E. Bhatia, P. Shah, K. Swain, S. Kaur, X. L. Li, J. Mwangi, O. Snapper, R. Nair, E. Agus, S. Ranganathan, J. Kage, J. Gao, J. N. Luo, A. Yu, F. Douam, Y. Tesfaigzi, J. Karp, N. Joshi
Abstract
Respiratory infections pose a global health crisis. Vaccines are pathogen specific, and new vaccines are needed for mutants and emerging pathogens. Here, we report a "drug free" prophylactic platform - a "Pathogen Capture and Neutralizing Spray" (PCANS) that acts via a multi-pronged approach to prevent a broad spectrum of respiratory infections. PCANS forms a protective coating in the nasal cavity that enhances the capture of large respiratory droplets. The coating acts as a physical barrier against a broad spectrum of viruses and bacteria, and rapidly neutralizes them, reducing the pathogen load by >99.99%. In mice, PCANS showed nasal retention for at least 8 h and was safe for daily administration. A single prophylactic dose of PCANS protected mice against supra-lethal dosages of a mouse-adapted H1N1 Influenza virus (PR8), reduced lung viral titer by >99.99%, improved survival, and suppressed pathological manifestations. Together, our data suggest PCANS as a promising daily-use prophylactic approach against current and emerging respiratory infections.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Formulation of a composite nasal spray enabling enhanced surface coverage and prophylaxis of SARS-COV-2
R. J. A. Moakes, S. P. Davies, … L. M. Grover·bioRxiv·Nov 18, 2020
- Mucin anchoring of SARS-CoV-2 neutralizing nanobinders increases intranasal antiviral efficacy
Joelton Rocha Gomes, Juliette Jacquelin, … Nicolas Meunier·bioRxiv·Apr 10, 2025
- Prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine.
R. Rathnasinghe, M. Salvatore, … A. Garcia-Sastre·bioRxiv·Apr 28, 2021
- An intranasal nanoparticle STING agonist has broad protective immunity against respiratory viruses and variants
A. Leekha, A. Saeedi, … N. Varadarajan·bioRxiv·Apr 18, 2022
- Intranasal administration of SARS-CoV-2 neutralizing human antibody prevents infection in mice
- A novel Pan-viral prophylaxis strategy using vaccine adjuvant CAF09b protects against influenza virus infection
J. Zimmermann, S. T. Schmidt, … D. Christensen·bioRxiv·Oct 21, 2021